The investment bank gave the company's stock an Outperform rating with a target price of $90 per share.
Executives at two commercial payors said they'd follow CMS' lead when it comes to patients covered under Medicare but beyond that their support for the agency's policy is less clear.
The registry from the American Society for Clinical Pathology aims to eventually collect metrics on how lab services impact patient outcomes.
CureOne also received CMS's approval for 11 quality metrics around biomarker testing that doctors can report for MIPS-related payment.
Lab industry groups hope to change CMS's controversial 2016 decision allowing nurses to perform complex lab tests.
Some industry players are accusing CMS of advancing backdoor LDT regulation by proposing to cover NGS tests with FDA approval/clearance, except in a limited setting.
ACLA alleges that HHS and CMS interpreted the Protecting Access to Medicare Act in a way that resulted in 2018 payment rates that are much lower than Congress intended.
The suit filed against the acting HHS secretary alleges that a flawed data collection process failed to establish market-based rates.
The final guidance is an update to an agreement between the FDA and CMS, which uses the FDA's policy in determining coverage for investigational devices.
Pricing for FoundationOne CDx, which received FDA approval and a proposed CMS national coverage determination yesterday, will be determined under PAMA.